---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-281246"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2026-06-24T21:02:19+00:00"
generated_at: "2026-06-24T21:04:20.072502+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CalciMedica raises ~$15M in private placement; FDA clears continued Auxora development

## Summary
- Private placement of 18.7M units at $0.8033 each; gross proceeds ~$15M, up to $34M additional from warrant exercises.
- FDA reviewed KOURAGE trial protocol amendment and interim safety data; no comments or questions, dosing may resume.
- Insiders including CEO, CBO, CMO, and major holders purchase ~6.9M units.
- Plans Phase 1b study of Auxora in pulmonary arterial hypertension (PAH) with data expected mid-2027.
- IND clearance for oral CM5480 anticipated mid-2027; cash runway into second half of 2027.

## SEC filing metadata
- accession: 0001193125-26-281246
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2026-06-24T21:02:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312526281246/0001193125-26-281246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312526281246/d142943d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-281246
- JSON: https://secwatch.observer/filing/0001193125-26-281246.json
- Plain text: https://secwatch.observer/filing/0001193125-26-281246.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.